NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Kiniksa reported strong Q2 2021 financial results driven by ARCALYST revenue growth.
Kiniksa Pharmaceuticals reported strong Q2 2021 results, driven by growth in ARCALYST revenue. The company is focused on advancing its pipeline and expanding ARCALYST's reach.
- Total revenue was $32.3 million, a 47% increase year-over-year.
- ARCALYST revenue was $31.7 million, a 49% increase year-over-year.
- Net loss was $25.9 million, compared to a net loss of $24.6 million for the same period in 2020.
- Cash, cash equivalents, and marketable securities were $212.1 million as of June 30, 2021.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$7.7M
Revenue by segment
Kiniksa · $31.7M total across 1 segment · Q2 2021
- ARCALYST$31.7M—100.0%
Forward guidance
Kiniksa anticipates ARCALYST revenue to be between $120.0 million and $130.0 million.
Tailwinds
- ARCALYST revenue between $120.0 million and $130.0 million
- Continued investment in ARCALYST
- Advancing mavrilimumab in GCA
- Advancing vixarelimab in prurigo nodularis
- Exploring partnering opportunities for IL-15 programs
Headwinds
- Uncertainties related to COVID-19
- Potential delays in clinical trials
- Regulatory risks
- Competition from other therapies
- Dependence on ARCALYST revenue
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro